Author pages are created from data sourced from our academic publisher partnerships and public sources.
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
IMPORTANCE Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this… Expand
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
- P. Tembhare, C. Yuan, +15 authors M. Stetler-Stevenson
- Biology, Medicine
- Leukemia research
- 1 March 2014
Flow cytometric (FC) enumeration of abnormal plasma cells (APCs) for diagnosis and prognostication of plasma cell dyscrasias (PCD) is challenging. We studied antigen expression in normal plasma cells… Expand
Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed…
Background An irreversible proteasome inhibitor with decreased peripheral neuropathy compared to bortezomib, Carfilzomib (Cz) has potent anti-MM effects resulting in deep clinical responses and… Expand
Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most debilitating toxicities associated with cancer treatment. In recent decades, significant strides have been made in our… Expand
Bendamustine: something old, something new
BackgroundBendamustine (Treanda, Ribomustin) is a water-soluble, bifunctional chemotherapeutic agent that also has potential antimetabolite properties and only partial cross-resistance with other… Expand
Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed
Medical literature detailing muscular complications of sickle cell anemia is sparse and limited to a few case-reports. Features consistent with myositis and myonecrosis are often overlooked and… Expand
Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
- S. Sethi, N. Tageja, +4 authors S. Revankar
- The American journal of the medical sciences
- 1 December 2009
Fibrolamellar carcinoma (FLC) is a rare malignant hepatocellular tumor of unknown etiology, arising almost exclusively from noninfected, noncirrhotic liver of young adults. FLC has traditionally been… Expand
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.
Currently, no reliable biomarkers are available to predict transformation from smoldering myeloma (SMM) to multiple myeloma (MM). Using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) we… Expand
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results… Expand